Rationale, Design, and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT)

American Journal of Cardiology

Volumn 80, Issue 9, 1997, Pages 1130-1133

  McCormick, Lisa S ^a   Black, Donald M ^a   Waters, David ^b   Brown, W Virgil ^c   Pitt, Bertram ^a,d  

^a PFIZER INC   (United States)

^b HARTFORD HOSPITAL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PYRROLES; RESEARCH DESIGN; STENTS;

EID: 0030671009     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00627-9     Document Type: Article

References (15)

1. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis percutaneous transluminal coronary angioplasty . N Engl J Med. 301:1979;61-68.
2. Havranek EP. Is cholesterol lowering an alternative to revascularization in some patients with coronary artery disease? Arch Intern Med. 155:1995;670-675.
3. Forrester J. Lipid lowering vs revascularization an idea whose time (for testing) has come . Circulation. 96:1997;1360-1362.
4. Campeau L. Letters to the editor grading of angina pectoris . Circulation. 54:1976;522-523.
5. Janicki JS, Weber KT. Equipment and protocols to evaluate the exercise response. In: Janicki JS, Weber KT, eds. Cardiopulmonary Exercise Testing. Philadelphia: WB Saunders, 1986;9:147.
6. Brasseur LA, Mairaux PH, Kandouci AB, Detry JM. Respiratory and metabolic parameters during submaximal and maximal exercise in normal men. Rulli V, Messin R, Denolin H. Normal Values in Adult Ergometry According to Age. 1983;3-14 Eur Soc Cardiol, Schiapparelli Farmaceutici Ed, Sex, and Training. Torino.
7. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston, Massachusetts, 1993.
8. Ware JE Jr, Sherbourne CD. The MOS 36-Item short-form health survey (SF-36). Med Care. 30:1992;6.
9. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard ACG. The QUinapril Ischemic Event Trial (QUIET) design and methods evaluation of chronic ACE inhibitor therapy after coronary artery intervention . Cardiovasc Drugs Therap. 7:1993;273-282.
10. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA. 260:1988;2849-2858.
11. Lee TH, Juarez G, Cook EF, Weisberg MC, Rouan GW, Brand DA, Goldman L. Ruling out acute myocardial infarction. N Engl J Med. 324:1991;1239-1246.
12. Agresti A. Categorical Data Analysis. 1990;230-232 John Wiley & Sons, Inc, New York.
13. Lawless JF. Statistical Models and Methods for Lifetime Data. 1982;343-395 John Wiley & Sons, Inc, New York.
14. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Contr Clin Trials. 2:1981;93-113.
15. Roberts WC. The underused miracle drugs the statin drugs are to atherosclerosis what penicillin was to infectious disease . Am J Cardiol. 78:1996;377-378.